Compound Profile
Lisdexamfetamine
Compound profile with evidence, safety, and practical fit.
Review needed — Review medications, pregnancy status, chronic conditions, and clinician guidance before use. Details
At a glance
From this profile's structured data- Evidence
- Grade C
- Profile context
- prodrug conversion to dextroamphetamine, dopamine and norepinephrine signaling
Controlled medication safety warning
U.S. Schedule II controlled substance. This research-only reference has not completed profile-level contraindication, interaction, or dosing review, so blank safety fields must not be interpreted as evidence of safety.
- Use only in lawful prescribing and dispensing contexts under qualified clinical supervision.
- Do not use this page to start, stop, change, share, source, or dose a controlled medication.
- Consult the current product-specific prescribing information for boxed warnings, contraindications, interactions, and monitoring requirements.
Quick stats
- Evidence level
- Limited evidence
- Typical onset
- Varies by prep
- Safety rating
- Review needed: Safety review pending
- Best for
- Prodrug Conversion To Dextroamphetamine, Dopamine And Norepinephrine Signaling
Safety
Safety & Cautions
Review medications, pregnancy status, chronic conditions, and clinician guidance before use.
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Interaction-AwareMedication or interaction context is explicitly noted.
- Stimulant-Like ProfileStimulant-like or activating caution language is present.
Evidence Summary
Profile-wide ·C LimitedEvidence lens
Read as directional context, not settled clinical proof.
Human clinical evidence: Present in source signals
Mechanistic / preclinical: Mechanism mapped
Research maturity: Emerging research — main contexts: Prodrug Conversion To Dextroamphetamine · Dopamine And Norepinephrine Signaling
Safety boundary: Safety note available — Review medications, pregnancy status, chronic conditions, and clinician guidance before use.
Confidence estimate based on the design quality and consistency of published clinical trials.
Lisdexamfetamine has a limited evidence rating.
Grade C: Limited Evidence
Evaluation of methodological rigor, population reach, and evidence alignment.
- Design Match
- Meta analysis
- Risk of Bias
- Low
- Consistency
- Consistent
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
Clinical Study Summaries (4)3 human evidence sources · 0 human trials · Participant totals not consistently reported · Consistency not yet classifiable
Filter by study class
Showing 4 of 4 studies.
What the evidence actually shows
This table contains 4 structured sources, including 3 human evidence sources; 0 are human trials.
| Study | Design | N | Dose | Duration | Population | Outcome | Result & magnitude | Source |
|---|---|---|---|---|---|---|---|---|
Background | Meta-analysis Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies. | — | — | — | — | — | A 2024 meta-analysis and review of 11 publications found lisdexamfetamine improved ADHD-RS-IV symptom outcomes versus placebo across the included child and adult trial literature; the review did not find clear symptom-management differences across the individual doses it pooled. | PubMed → |
Background | Meta-analysis Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies. | — | — | — | — | — | A 2018 network meta-analysis found short-term ADHD symptom benefit for the amphetamine class, which included lisdexamfetamine, versus placebo in clinician ratings across age groups; comparative estimates and tolerability varied by age and outcome source. | PubMed → |
Background | Meta-analysis Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies. | — | — | — | — | — | A 2025 network meta-analysis found lisdexamfetamine was among ADHD medications associated with increases in haemodynamic measures versus placebo in at least one age group or parameter, while certainty varied and randomized follow-up was predominantly short term. | PubMed → |
Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | Current U.S. labeling identifies lisdexamfetamine dimesylate as a Schedule II central nervous system stimulant indicated for ADHD in adults and pediatric patients 6 years and older and for moderate to severe binge eating disorder in adults, and carries a boxed warning about abuse, misuse, and addiction. | Source → |
Dosing
- No standardized dose
- No standardized dose is established for this ingredient in our source data. Preparations differ widely, so follow the standardization on the product you actually have and speak to a clinician before starting.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the Lisdexamfetamine evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Sourcing options disabled for safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions above under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?